Alkem signs licensing agreement with Harvard University’s Office of Technology Development
Alkem Laboratories has signed a license agreement with Harvard University’s Office of Technology Development (OTD) allowing Alkem to develop and commercialize a new technology that could help meet the urgent need for an effective treatment of diabetic neuropathy, foot ulcers, peripheral arterial disease (PAD), and other injuries caused by vascular disease.
The license grants Alkem commercialization rights in the United States and India.
Powered by Capital Market – Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)